ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NATR
PYXS (27) SIGA (68) KROS (64) KRRO (40) ⌘ Pro Terminal →

Nature's Sunshine Products Inc. (NATR) — RQD Stock Rating Cockpit

$12.02 -1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.96

Nature's Sunshine Products Inc. (NATR) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $215.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NATR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $12.02 (-1.88% 1D, market cap $215.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, NATR ranks #131 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NATR compare to PYXS and SIGA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C (64/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, PYXS (Pyxis Oncology Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $216.4M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $218.4M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NATR?
▼

Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.96 (-0.53%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C
Cash (16)Whales (4)SEC (16)Macro (10)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$30 Bull$12 Base$10 Bear
📬 FREE NATR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NATR)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY NATR SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 6% FCF Margin ($28.8M FCF) & 72.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
72
Grade B$12.76-0.4% Next Q
Q2 (-2Q)
69
Grade B-$12.71-2.5% Next Q
Q3 (-1Q)
67
Grade B-$12.39-3% Next Q
Current
64
Grade C$12.02+1.1% Hist 90D α
Trajectory: B (72) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NATR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, NATR faces multiple-compression risk if 11.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.00) or 200D SMA ($20.44) invalidates the momentum regime and cuts Target Base ($12.34) toward Bear Floor ($9.63).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NATR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NATR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
4.33>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $12$12.02H: $28
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (72.4% gross margin and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on NATR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

28.9% ROIC with 72.4% gross margin and 13.35% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 4.33 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (53)

22/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like NATR
  • ✓Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NATR Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NATR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.82%▲ RESISTANCE BREAKOUT
2026-11-03O $12.28H $12.28L $12.02C $12.02VOL 99.4K
RES: $10.92SUP: $11.34SMA50: $13.00SMA200: $20.44
$28.18$23.79$19.41$15.02$10.64RES $10.92SUP $11.34$12.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NATR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NATR Butterfly Map → + Track NATR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
0.9%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NATR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NATR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NATR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NATR)

Health Care Rank #131 of 1015 ⚔️ PYXS vs NATR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NATR vs. PYXS, SIGA, KROS, KRRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nature's Sunshine Products Inc. (NATR) ranks #131 by composite RQD confidence (64/100, grade C) and #564 by equity capitalization ($215.5M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with NATR at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NATR ACTIVE
Nature's Sunshine Products Inc.
C 64/100 11.1x 72.4% 28.9% -1.88% $215.5M Benchmark Subject
PYXS
Pyxis Oncology Inc.
E 27/100 — 82.8% -35.0% -6.63% $216.4M /pyxs-vs-natr →
SIGA
SIGA Technologies Inc.
C+ 68/100 9.8x 68.6% 42.7% -2.96% $218.4M /siga-vs-natr →
KROS
Keros Therapeutics Inc.
C 64/100 — — 85.0% -2.54% $218.9M /kros-vs-natr →
KRRO
Korro Bio Inc.
D- 40/100 — — -35.0% +10.69% $210.8M /krro-vs-natr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000275053 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported GAAP revenue of $480.1M (+5.7% vs. FY2024 revenue of $454.4M , and +7.8% cumulative change since FY2023) , GAAP net income of $19.5M, operating cash flow of $35.3M, and free cash flow of $28.8M (+101.3% YoY). On the balance sheet, NATR closed FY2025 with $261.1M in total assets against $0 in total debt (Altman Z-Score: 4.33, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $480.1M $19.5M $35.3M $28.8M $261.1M —
FY2024 (FY) 2024-12-31 $454.4M $7.7M $25.3M $14.3M $240.9M —
FY2023 (FY) 2023-12-31 $445.3M $15.1M $41.2M $41.2M — —

3. NATR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $12.02 (-1.88% 1D, market cap $215.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, NATR ranks #131 in composite RQD confidence.

How does NATR compare to PYXS and SIGA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C (64/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, PYXS (Pyxis Oncology Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $216.4M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $218.4M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NATR?

Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NATR trading relative to its 50-day, 200-day, and 52-week technical levels?

NATR last traded at $12.02 (-1.88% on volume of 140,796 shares), positioning the stock -7.54% below its 50-day simple moving average ($13.00) and -41.19% below its 200-day simple moving average ($20.44). Across its 52-week range of $12.00 to $28.14, NATR sits at the 0.1% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($11.29 to $12.75).

Direct Sub-Reports: NATR RQD Cockpit NATR 12M Forecast NATR Earnings & Move NATR Dividends & DRIP NATR Insiders & 13F NATR Whale Options NATR Profit Sankey NATR News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

NATR — Nature's Sunshine Products Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nature's Sunshine Products Inc. (NATR) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $12.02 (-1.88% 1D, market capitalization $215.5M).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 28.9%, gross margin of 72.4%, operating margin of 5.2%, and free cash flow yield of 13.35%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.33, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nature's Sunshine Products Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Market capitalization is reported as $0.2B (per the company profile). Gross margin is 72.4% (per market data), indicating the reported business carries a high gross margin profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported $480.1M in annual revenue (up from $454.4M in FY2024, +5.7% YoY) and $19.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($445.3M revenue, $15.1M net income) through FY2025, NATR scaled operating cash flow to $35.3M and free cash flow to $28.8M, backed by $261.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $12.00 – $28.14 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 11.1x trailing P/E and 4.0x EV/EBITDA against 5.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NATR carries a macro regime beta of 1.00 and gross margin of 72.4%.

  • Key Question #1: Can NATR sustain or expand its 5.2% operating margin and 28.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $480.1M and free cash flow of $28.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NATR's 10.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NATR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nature's Sunshine Products Inc. (NATR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NATR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NATR Bull vs. Bear Conversation Board — What's Your Call at $12.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NATR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NATR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $15.44 (+26.0%)
📌 Pinned Debate

Cash-generation metrics (ROIC 28.9%, FCF yield 13.35%) and a low P/E of 11.1 combine with a strong forensic balance sheet (Altman Z 4.3

Long NATR at $12.25 targeting $15.44. Cash-generation metrics (ROIC 28.9%, FCF yield 13.35%) and a low P/E of 11.1 combine with a strong forensic balance sheet (Altman Z 4.33, Piotroski F 8/9).. Institutional whale score is 4/20 and the risk/reward vs. the $12.00 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 4/20 institutional whale-flow stock at $12.25 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $10.29 (-16.0%)
Spot @ $12.25

Thin operating margin of 5.2%, weak whale 13F flow (6/20), and a conditional 'Watch for Breakout' verdict leave the rating short of a b

Sitting on the sidelines or leaning short NATR above $12.25. Thin operating margin of 5.2%, weak whale 13F flow (6/20), and a conditional 'Watch for Breakout' verdict leave the rating short of a buy signal.. Until Fundamental Cash Engine (16/20) and FCF yield (13.35%) inflect higher, upside is capped near $28.14.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%